<?xml version="1.0" encoding="UTF-8"?>
<list>
  <sentences>
    <s path="[OANC]/data/written_2/technical/biomed/1471-2350-4-2.anc" start="22557" end="22560" sStart="22545" offset="12" sid="r8.way.n.0508" wn="1" wnkey="way%1:07:01::" annotator="cgozo" text="Put another way, population heterozygote advantage may appear due to a combination of the two distinct mechanisms we defined in the Introduction: the protective or detrimental effects of particular alleles (R and S alleles in our model), and the effects of heterozygosity itself." />
    <s path="[OANC]/data/written_2/technical/biomed/1471-2350-4-2.anc" start="15299" end="15303" sStart="null" offset="21" sid="r11.true.j.0412" wn="1" wnkey="true%3:00:00::" annotator="vebatchelder" text="The converse is also true, though only in what seem to be very special circumstances." />
    <s path="[OANC]/data/written_2/technical/biomed/1471-2350-4-2.anc" start="23647" end="23651" sStart="null" offset="150" sid="r11.true.j.0393" wn="1" wnkey="true%3:00:00::" annotator="adelpriore" text="For example, if genotypes XX, XY and YY have relative risks 0.6, 2.1, and 1 for clearance of a viral infection, then this should hold true regardless of who else is in the population." />
    <s path="file:/c:/OANC/data/written_2/technical/biomed/1471-2350-4-2.anc" start="13708" end="13713" sStart="null" offset="0" sid="null" wn="5" wnkey="show%2:36:00::" annotator="elstickles" text="Figure 1&lt;b&gt;shows&lt;/b&gt; the parameter regions in which population heterozygote advantage is expected and those in which the contrary is expected: homozygotes on average are more likely to have a favorable disease course." />
    <s path="file:/c:/OANC/data/written_2/technical/biomed/1471-2350-4-2.anc" start="13708" end="13713" sStart="null" offset="0" sid="null" wn="5" wnkey="show%2:36:00::" annotator="carichter" text="Figure 1&lt;b&gt;shows&lt;/b&gt; the parameter regions in which population heterozygote advantage is expected and those in which the contrary is expected: homozygotes on average are more likely to have a favorable disease course." />
    <s path="file:/c:/OANC/data/written_2/technical/biomed/1471-2350-4-2.anc" start="4800" end="4805" sStart="null" offset="0" sid="null" wn="6" wnkey="show%2:32:02::" annotator="carichter" text="In many cases, heterozygotes as a group have &lt;b&gt;shown&lt;/b&gt; better infectious disease outcomes (slower disease progression or more rapid clearance of viral infection) than homozygotes as a group [ 5 6 8 9 14 22 ] , a phenomenon we call &quot;population heterozygote advantage.&quot;" />
    <s path="[OANC]/data/written_2/technical/biomed/1471-2350-4-2.anc" start="22058" end="22064" sStart="null" offset="79" sid="r11.refer.v.0063" wn="1" wnkey="refer%2:32:01::" annotator="anfahmy" text="Note, however, that &quot;no effect&quot; is also a relative term, and refers to an allele whose effect on disease outcome is close to the population average." />
    <s path="[OANC]/data/written_2/technical/biomed/1471-2350-4-2.anc" start="11516" end="11521" sStart="null" offset="494" sid="r11.refer.v.0600" wn="6" wnkey="refer%2:32:00::" annotator="adelpriore" text="It can also accommodate overdominance of the resistant alleles ( a &gt; 1; b &gt; d ; c &gt; d ), in which each heterozygote does better than either corresponding homozygote, and underdominance, in which each heterozygote does worse than either corresponding homozygote ( a &lt; 1; b &lt; 1; c &lt; d ). In this model, susceptibility and resistance are relative and simply refer respectively to lower and higher probabilities of favorable disease course, given infection." />
    <s path="[OANC]/data/written_2/technical/biomed/1471-2350-4-2.anc" start="22058" end="22064" sStart="null" offset="79" sid="r11.refer.v.0063" wn="6" wnkey="refer%2:32:00::" annotator="adelpriore" text="Note, however, that &quot;no effect&quot; is also a relative term, and refers to an allele whose effect on disease outcome is close to the population average." />
    <s path="file:/D:/Corpora/oanc/data/written_2/technical/biomed/1471-2350-4-2.anc" start="4893" end="4898" sStart="null" offset="0" sid="null" wn="1" wnkey="rapid%5:00:00:fast:01" annotator="veweser" text="In many cases, heterozygotes as a group have shown better infectious disease outcomes (slower disease progression or more &lt;b&gt;rapid&lt;/b&gt; clearance of viral infection) than homozygotes as a group [ 5 6 8 9 14 22 ] , a phenomenon we call &quot;population heterozygote advantage.&quot;" />
    <s path="file:/D:/Corpora/oanc/data/written_2/technical/biomed/1471-2350-4-2.anc" start="4893" end="4898" sStart="null" offset="0" sid="null" wn="1" wnkey="rapid%5:00:00:fast:01" annotator="carichter" text="In many cases, heterozygotes as a group have shown better infectious disease outcomes (slower disease progression or more &lt;b&gt;rapid&lt;/b&gt; clearance of viral infection) than homozygotes as a group [ 5 6 8 9 14 22 ] , a phenomenon we call &quot;population heterozygote advantage.&quot;" />
    <s path="[OANC]/data/written_2/technical/biomed/1471-2350-4-2.anc" start="17480" end="17484" sStart="null" offset="107" sid="r7.poor.j.0498" wn="5" wnkey="poor%5:00:00:insufficient:00" annotator="jeneale" text="Dominance of particular HLA alleles conferring resistance, and/or recessiveness of susceptibility (poor outcome) alleles, have been documented for schistosomiasis [ 24 ] , leprosy [ 25 ] , acute lymphoblastic leukemia (for which an infectious cause is hypothesized) [ 26 ] , and hepatitis B (in this case the outcome was vaccine responsiveness) [ 27 ] ." />
    <s path="[OANC]/data/written_2/technical/biomed/1471-2350-4-2.anc" start="8374" end="8384" sStart="null" offset="364" sid="r10.particular.j.0861" wn="2" wnkey="particular%5:00:02:specific:00" annotator="veweser" text="To determine the precise conditions under which population heterozygote advantage will be observed, we consider a general model that predicts the expected outcome of a comparison between heterozygotes and homozygotes in an epidemiological study as a function of (i) the frequencies of resistant and susceptible alleles at a particular locus and (ii) the relationship between genotype at that locus and phenotype." />
    <s path="[OANC]/data/written_2/technical/biomed/1471-2350-4-2.anc" start="1669" end="1679" sStart="null" offset="350" sid="r10.particular.j.0497" wn="2" wnkey="particular%5:00:02:specific:00" annotator="veweser" text="A second, distinct but compatible hypothesis was suggested by Doherty and Zinkernagel soon after their discovery of MHC restriction: since each MHC allele provides an infected individual with the ability to present a particular set of antigens, individuals who are heterozygous (say, genotype XY) at a particular MHC locus may mount a more vigorous immune response to a given infection, resulting in a better outcome, than individuals who are homozygous for either of the corresponding alleles (XX or YY) [ 4 ] ." />
    <s path="[OANC]/data/written_2/technical/biomed/1471-2350-4-2.anc" start="22764" end="22774" sStart="null" offset="219" sid="r10.particular.j.0995" wn="1" wnkey="particular%5:00:00:specific:00" annotator="cgozo" text="Put another way, population heterozygote advantage may appear due to a combination of the two distinct mechanisms we defined in the Introduction: the protective or detrimental effects of particular alleles (R and S alleles in our model), and the effects of heterozygosity itself." />
    <s path="[OANC]/data/written_2/technical/biomed/1471-2350-4-2.anc" start="3588" end="3598" sStart="null" offset="132" sid="r10.particular.j.0668" wn="1" wnkey="particular%5:00:00:specific:00" annotator="brubin" text="Of the two ways described above in which MHC genotype may affect disease outcome, the first - association between a particular allele and disease outcome - has been repeatedly documented in human populations by various methods of genetic epidemiology [ 17 ] . The second kind of effect, more vigorous immune responses to a pathogen by a heterozygote as compared to homozygotes for the same alleles, which we term &quot;allele-specific overdominance,&quot; has been suggested by several animal studies [ 18 19 20 21 ] , although none of these studies is unambiguous (see DISCUSSION)." />
    <s path="[OANC]/data/written_2/technical/biomed/1471-2350-4-2.anc" start="18252" end="18262" sStart="null" offset="105" sid="r10.particular.j.0316" wn="1" wnkey="particular%5:00:00:specific:00" annotator="brubin" text="Example 2: Suppose there are 10 alleles, each with frequency 5%, each conferring resistance to a particular disease, and one allele, with frequency 50%, conferring susceptibility." />
    <s path="[OANC]/data/written_2/technical/biomed/1471-2350-4-2.anc" start="21549" end="21559" sStart="null" offset="165" sid="r10.particular.j.0232" wn="2147483645" wnkey="null" annotator="brubin" text="Both of these examples were chosen for the purposes of clarity, rather than for precise reflection of the allele frequencies in real populations; in particular, few if any populations have a single HLA allele with a frequency of 50%." />
    <s path="[OANC]/data/written_2/technical/biomed/1471-2350-4-2.anc" start="13190" end="13196" sStart="null" offset="390" sid="r10.common.j.0741" wn="4" wnkey="common%5:00:00:familiar:02" annotator="veweser" text="Using the relative risk equation above, it can be shown by taking partial derivatives with respect to the parameters p , ? and ?, that (under the assumptions stated above) the relative risk increases with p and ? and decreases with ?. Thus, population heterozygote advantage is most likely to be observed when resistant alleles are common ( p large) but highly diverse (? is small), and when susceptible alleles are not diverse (large ?)." />
    <s path="[OANC]/data/written_2/technical/biomed/1471-2350-4-2.anc" start="13517" end="13523" sStart="null" offset="151" sid="r10.common.j.0089" wn="4" wnkey="common%5:00:00:familiar:02" annotator="veweser" text="Homozygotes will be predominantly resistant if R alleles are common and have little diversity and sensitive when S alleles are common and have little diversity." />
    <s path="[OANC]/data/written_2/technical/biomed/1471-2350-4-2.anc" start="13517" end="13523" sStart="null" offset="151" sid="r10.common.j.0089" wn="3" wnkey="common%5:00:00:shared:00" annotator="cgozo" text="Homozygotes will be predominantly resistant if R alleles are common and have little diversity and sensitive when S alleles are common and have little diversity." />
    <s path="[OANC]/data/written_2/technical/biomed/1471-2350-4-2.anc" start="13517" end="13523" sStart="null" offset="151" sid="r10.common.j.0089" wn="4" wnkey="common%5:00:00:familiar:02" annotator="brubin" text="Homozygotes will be predominantly resistant if R alleles are common and have little diversity and sensitive when S alleles are common and have little diversity." />
    <s path="[OANC]/data/written_2/technical/biomed/1471-2350-4-2.anc" start="13517" end="13523" sStart="null" offset="151" sid="r10.common.j.0089" wn="2" wnkey="common%3:00:01::" annotator="anfahmy" text="Homozygotes will be predominantly resistant if R alleles are common and have little diversity and sensitive when S alleles are common and have little diversity." />
    <s path="[OANC]/data/written_2/technical/biomed/1471-2350-4-2.anc" start="22632" end="22643" sStart="null" offset="87" sid="r11.combination.n.0958" wn="1" wnkey="combination%1:14:00::" annotator="vebatchelder" text="Put another way, population heterozygote advantage may appear due to a combination of the two distinct mechanisms we defined in the Introduction: the protective or detrimental effects of particular alleles (R and S alleles in our model), and the effects of heterozygosity itself." />
    <s path="[OANC]/data/written_2/technical/biomed/1471-2350-4-2.anc" start="15151" end="15163" sStart="null" offset="84" sid="r11.combination.n.0305" wn="1" wnkey="combination%1:14:00::" annotator="anfahmy" text="Figure 1shows that this is possible under a fairly broad range of parameter combinations (i.e." />
  </sentences>
</list>